{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:31:45Z","timestamp":1790285505072,"version":"4.1.0"},"reference-count":74,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Background\/Objectives: Hand, foot and mouth disease (HFMD) caused by enterovirus 71 (EV71) may cause severe complications and death in children. It is also a common cause of outbreaks in the Asia-Pacific Region. Incidence among children 1 to &lt;2 years was over 3000\/100,000 population in China. A systematic review and meta-analysis was performed to review evidence on vaccine efficacy (VE), immunogenicity, and safety of two doses of EV71 vaccine in children. Methods: Randomized controlled trials (RCTs) comparing EV71 vaccine with placebo or with another EV71 vaccine in children and adolescents aged \u226418 years were searched on PubMed, Medline, Embase, CENTRAL, and CNKI (Chinese) in week 5 November 2024. The reference list of each study and the websites of vaccine manufacturers were also searched. The Cochrane Risk of Bias 2 tool (RoB2) was used to assess the risk of bias. VE, immunogenicity (including seropositive rate, seroconversion rate, geometric mean titer (GMT), Geometric Mean Fold Increase (GMFI)), and rate of adverse events were analyzed. Results: A total of 4199 articles were identified, and 25 studies were finally included. VE (%) against EV71 HFMD in children aged \u22645 years at 12 months was 94.8% (95%CI 87.2\u201397.9) for Sinovac and 90.9% (95%CI 70.4\u201397.2) for Wuhan Institute of Biological Products (WIBP), while the Chinese Academy of Medical Sciences (CAMS) reported 97.4% (95%CI 92.9\u201399.0) at 11 months. At 1 month after the second dose, 99.19% (95%CI 98.15\u201399.65) of children aged \u22645 years in the vaccine group were seropositive, and 96.30% (95%CI 92.71\u201398.17) achieved seroconversion. GMT at 1 month after the second dose in the vaccine group was 46.78 (95%CI 26.18\u201383.61) times that in the placebo group. GMFI at 1 month after the second dose in the vaccine group was 28.41 (95%CI 22.18\u201336.39) times that of the placebo group. The rate of serious adverse events (AEs) was lower in the vaccine group than the placebo group (1.23% (95%CI 0.58\u20132.69) vs. 1.34% (95%CI 0.58\u20133.07)) at 1 month after the second dose. There was no significant difference in other adverse events between the vaccine and placebo groups. Conclusions: EV71 vaccines were effective, immunogenic and safe. Areas with a high incidence of EV71 may consider introducing EV71 vaccines.<\/jats:p>","DOI":"10.3390\/vaccines14030235","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T13:11:36Z","timestamp":1772629896000},"page":"235","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy, Immunogenicity, and Safety of Enterovirus 71 Vaccines in Children: A Systematic Review and Meta-Analysis"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-9138-9880","authenticated-orcid":false,"given":"Guan Xing","family":"Lai","sequence":"first","affiliation":[{"name":"Department of Health, Centre for Health Protection, Communicable Disease Branch, Hong Kong SAR, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert Ka Wing","family":"Au","sequence":"additional","affiliation":[{"name":"Department of Health, Centre for Health Protection, Communicable Disease Branch, Hong Kong SAR, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3071-6256","authenticated-orcid":false,"given":"Edmond Siu Keung","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Health, Centre for Health Protection, Infection Control Branch, Hong Kong SAR, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,4]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2026, February 08). A Guide to Clinical Management and Public Health Response for Hand, Foot and Mouth Disease (HFMD). Available online: https:\/\/iris.who.int\/bitstream\/handle\/10665\/207490\/9789290615255_eng.pdf?sequence=1&isAllowed=y."},{"key":"ref_2","unstructured":"Centre for Health Protection (2026, February 08). Hand, Foot and Mouth Disease, Available online: https:\/\/www.chp.gov.hk\/en\/healthtopics\/content\/24\/23.html."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e775","DOI":"10.1016\/j.ijid.2010.02.2265","article-title":"The enterovirus 71 epidemic in 2008\u2014Public health implications for Hong Kong","volume":"14","author":"Ma","year":"2010","journal-title":"Int. J. Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12929-019-0552-7","article-title":"Enterovirus A71 neurologic complications and long-term sequelae","volume":"26","author":"Chang","year":"2019","journal-title":"J. Biomed. Sci."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e59449","DOI":"10.2196\/59449","article-title":"Epidemiological Survey of Enterovirus Infections in Taiwan From 2011 to 2020: Retrospective Study","volume":"10","author":"Liu","year":"2024","journal-title":"JMIR Public Health Surveill"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1542\/peds.102.5.1126","article-title":"Clinical and economic impact of enterovirus illness in private pediatric practice","volume":"102","author":"Pichichero","year":"1998","journal-title":"Pediatrics"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Zheng, Y., Jit, M., Wu, J.T., Yang, J., Leung, K., Liao, Q., and Yu, H. (2017). Economic costs and health-related quality of life for hand, foot and mouth disease (HFMD) patients in China. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0184266"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Chiu, N.C., Lin, C.Y., Chen, C., Cheng, H.Y., Hsieh, E.F., Liu, L.T., Chiu, C.H., and Huang, L.M. (2024). Long-Term Immunogenicity Study of an Aluminum Phosphate-Adjuvanted Inactivated Enterovirus A71 Vaccine in Children: An Extension to a Phase 2 Study. Vaccines, 12.","DOI":"10.2139\/ssrn.4898445"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1016\/S0140-6736(22)00313-0","article-title":"Efficacy, safety, and immunogenicity of an inactivated, adjuvanted enterovirus 71 vaccine in infants and children: A multiregion, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"399","author":"Nguyen","year":"2022","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"422","DOI":"10.7883\/yoken.63.422","article-title":"Changing epidemiology of hand, foot, and mouth disease in Hong Kong, 2001\u20132009","volume":"63","author":"Ma","year":"2010","journal-title":"Jpn. J. Infect. Dis."},{"key":"ref_11","first-page":"147","article-title":"Trend of epidemics and variation of pathogens of hand, foot and mouth disease in China: A dynamic series analysis","volume":"40","author":"Zhang","year":"2019","journal-title":"Chin. J. Epidemiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1097\/INF.0b013e3182127782","article-title":"Effects of public health interventions in reducing transmission of hand, foot, and mouth disease","volume":"30","author":"Ma","year":"2011","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_13","unstructured":"World Health Organization (2018). China Produces World\u2019s First Vaccine Against Virus that Causes Hand, Foot and Mouth Disease, World Health Organization."},{"key":"ref_14","unstructured":"(2026, February 08). Chinese Academy of Medical Sciences Enterovirus 71 Inactivated Vaccine (Human Diploid Cell) Product Insert. Available online: https:\/\/www.meipian.cn\/hoh949k."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"101596","DOI":"10.1016\/j.eclinm.2022.101596","article-title":"Immunogenicity and safety of an enterovirus 71 vaccine in children aged 36\u201371 months: A double-blind, randomised, similar vaccine-controlled, non-inferiority phase III trial","volume":"52","author":"Tong","year":"2022","journal-title":"EClinicalMedicine"},{"key":"ref_16","unstructured":"National Medical Products Administration (2026, February 08). Data Enquiry, Available online: https:\/\/www.nmpa.gov.cn\/datasearch\/home-index.html."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1080\/21645515.2018.1442997","article-title":"Five-year immunity persistence following immunization with inactivated enterovirus 71 type (EV71) vaccine in healthy children: A further observation","volume":"14","author":"Hu","year":"2018","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_18","unstructured":"Sinovac Biotech (2026, February 08). Enterovirus 71 Inactivated Vaccine (Vero Cell) Product Insert. Available online: http:\/\/www.sinovac.com\/file\/info\/20220427\/2022changdao_shuoming.pdf."},{"key":"ref_19","unstructured":"Wuhan Institute of Biological Products (2026, February 08). Enterovirus 71 Inactivated Vaccine (Vero Cell) Product Insert. Available online: http:\/\/www.wibp.com.cn\/Manage\/Upload\/202401181659500088924616998.pdf."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1016\/j.vaccine.2019.02.023","article-title":"Immunogenicity, safety, cross-reaction, and immune persistence of an inactivated enterovirus A71 vaccine in children aged from two months to 11 years in Taiwan","volume":"37","author":"Huang","year":"2019","journal-title":"Vaccine"},{"key":"ref_21","unstructured":"Food and Drug Administration, and Ministry of Health and Welfare (2026, February 08). Envacgen, Available online: https:\/\/mcp.fda.gov.tw\/im_detail_1\/%E8%A1%9B%E9%83%A8%E8%8F%8C%E7%96%AB%E8%A3%BD%E5%AD%97%E7%AC%AC000152%E8%99%9F."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"5559","DOI":"10.1016\/j.vaccine.2019.07.096","article-title":"Immunogenicity and safety of an inactivated enterovirus A71 vaccine in children 3\u20136 years and 2\u201335 months of age- an open-label, randomized phase IIb clinical trial","volume":"37","author":"Hung","year":"2019","journal-title":"Vaccine"},{"key":"ref_23","unstructured":"Food and Drug Administration, and Ministry of Health and Welfare (2026, February 08). EnVAX-A71, Available online: https:\/\/mcp.fda.gov.tw\/im_detail_1\/%E8%A1%9B%E9%83%A8%E8%8F%8C%E7%96%AB%E8%A3%BD%E5%AD%97%E7%AC%AC000149%E8%99%9F."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_25","unstructured":"Chinese Academy of Medical Sciences (2026, February 08). Enterovirus 71 Inactivated Vaccine (Human Diploid Cell). Available online: https:\/\/www.imbcams.ac.cn\/cpzx\/cpjs\/content_4684."},{"key":"ref_26","unstructured":"Sinovac Biotech (2026, February 08). Review on Clinical Researchs of Sinovac Inlive EV71 Vaccine 6 Years After Its Marketing. Available online: http:\/\/www.sinovac.com\/zh-cn\/news\/id-3130."},{"key":"ref_27","unstructured":"Wuhan Institute of Biological Products (2026, February 08). Prevention Products. Available online: http:\/\/www.wibp.com.cn\/list.php?id=14."},{"key":"ref_28","unstructured":"Medigen Vaccine Biologics (2026, February 08). Enterovirus 71 Vaccine. Available online: https:\/\/www.medigenvac.com\/research_vaccine_view.php?id=4."},{"key":"ref_29","unstructured":"Enimmune (2026, February 08). Literature on EnVAX-A71. Available online: http:\/\/www.enimmune.com.tw\/tw\/news\/%E5%85%AC%E9%96%8B%E6%96%87%E7%8D%BB%E7%99%BC%E8%A1%A8\/%E5%AE%89%E6%8B%93%E4%BC%8F-EnVAX-A71-%E6%96%87%E7%8D%BB."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"ref_31","unstructured":"Cochrane Collaboration (2025). Chapter 10: Analysing data and undertaking meta-analyses. Cochrane Handbook for Systematic Reviews of Interventions, Cochrane Collaboration."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1016\/j.vaccine.2012.03.010","article-title":"Safety and immunogenicity of a novel human Enterovirus 71 (EV71) vaccine: A randomized, placebo-controlled, double-blind, Phase I clinical trial","volume":"30","author":"Li","year":"2012","journal-title":"Vaccine"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1093\/infdis\/jit429","article-title":"Immunogenicity, safety, and immune persistence of a novel inactivated human enterovirus 71 vaccine: A phase II, Randomized, double-blind, placebo-controlled Trial","volume":"209","author":"Li","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1128\/CVI.00491-13","article-title":"Immunogenicity, safety, and lot consistency of a novel inactivated enterovirus 71 vaccine in Chinese children aged 6 to 59 months","volume":"20","author":"Hu","year":"2013","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1080\/14760584.2018.1430572","article-title":"A comparative analysis of immunogenicity and safety of an enterovirus 71 vaccine between children aged 3\u20135 years and infants aged 6\u201335 months","volume":"17","author":"Gu","year":"2018","journal-title":"Expert Rev. Vaccines"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1056\/NEJMoa1304923","article-title":"Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China","volume":"370","author":"Zhu","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1586\/14760584.2016.1096782","article-title":"Two-year efficacy and immunogenicity of Sinovac Enterovirus 71 vaccine against hand, foot and mouth disease in children","volume":"15","author":"Li","year":"2016","journal-title":"Expert Rev. Vaccines"},{"key":"ref_38","first-page":"20153198409","article-title":"Consistency of various batches of inactivated enterovirus 71 vaccine","volume":"28","author":"Zhang","year":"2015","journal-title":"Chin. J. Biol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1303224","article-title":"An inactivated enterovirus 71 vaccine in healthy children","volume":"370","author":"Li","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Liu, L., Mo, Z., Liang, Z., Zhang, Y., Li, R., Ong, K.C., Wong, K.T., Yang, E., Che, Y., and Wang, J. (2015). Immunity and clinical efficacy of an inactivated enterovirus 71 vaccine in healthy Chinese children: A report of further observations. BMC Med., 13.","DOI":"10.1186\/s12916-015-0448-7"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1080\/21645515.2015.1115934","article-title":"Comprehensive safety assessment of a human inactivated diploid enterovirus 71 vaccine based on a phase III clinical trial","volume":"12","author":"Zhang","year":"2016","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1097\/INF.0b013e31826eba74","article-title":"Reactogenicity and immunogenicity of an enterovirus 71 vaccine in Chinese healthy children and infants","volume":"31","author":"Zhu","year":"2012","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/S0140-6736(12)61764-4","article-title":"Immunogenicity and safety of an enterovirus 71 vaccine in healthy Chinese children and infants: A randomised, double-blind, placebo-controlled phase 2 clinical trial","volume":"381","author":"Zhu","year":"2013","journal-title":"Lancet"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1016\/S0140-6736(13)61049-1","article-title":"Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"381","author":"Zhu","year":"2013","journal-title":"Lancet"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.4161\/hv.28397","article-title":"Clinical evaluation for batch consistency of an inactivated enterovirus 71 vaccine in a large-scale phase 3 clinical trial","volume":"10","author":"Chen","year":"2014","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1093\/infdis\/jiw502","article-title":"2-Year Efficacy, Immunogenicity, and Safety of Vigoo Enterovirus 71 Vaccine in Healthy Chinese Children: A Randomized Open-Label Study","volume":"215","author":"Wei","year":"2017","journal-title":"J. Infect. Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2063630","DOI":"10.1080\/21645515.2022.2063630","article-title":"Clinical evaluation of the lot-to-lot consistency of an enterovirus 71 vaccine in a commercial-scale phase IV clinical trial","volume":"18","author":"Chen","year":"2022","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1016\/j.vaccine.2020.02.013","article-title":"Interchangeability of two Enterovirus 71 inactivated vaccines in Chinese children: A phase IV, open-label, and randomized controlled trial","volume":"38","author":"Xu","year":"2020","journal-title":"Vaccine"},{"key":"ref_49","first-page":"100284","article-title":"Immunogenicity and safety of inactivated enterovirus A71 vaccines in children aged 6-35 months in China: A non-inferiority, randomised controlled trial","volume":"16","author":"Li","year":"2021","journal-title":"Lancet Reg. Health West. Pac."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/jpids\/piaa129","article-title":"Immunogenicity and Safety of Inactivated Enterovirus 71 Vaccine in Children Aged 36-71 Months: A Double-Blind, Randomized, Controlled, Non-inferiority Phase III Trial","volume":"10","author":"Zhang","year":"2021","journal-title":"J. Pediatr. Infect. Dis. Soc."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1080\/14760584.2016.1191357","article-title":"Enterovirus 71: A whole virion inactivated enterovirus 71 vaccine","volume":"15","author":"Zhou","year":"2016","journal-title":"Expert Rev. Vaccines"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Li, M.L., Shih, S.R., Tolbert, B.S., and Brewer, G. (2021). Enterovirus A71 Vaccines. Vaccines, 9.","DOI":"10.3390\/vaccines9030199"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Liu, P., Yuan, Y., Cui, B., Huo, Y., Bian, L., Chen, L., Liu, S., Wang, C., Xu, Y., and Tedcastle, A. (2021). Cross-Antigenicity between EV71 Sub-Genotypes: Implications for Vaccine Efficacy. Viruses, 13.","DOI":"10.3390\/v13050720"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Mao, Q., Cheng, T., Zhu, F., Li, J., Wang, Y., Li, Y., Gao, F., Yang, L., Yao, X., and Shao, J. (2013). The cross-neutralizing activity of enterovirus 71 subgenotype c4 vaccines in healthy chinese infants and children. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0079599"},{"key":"ref_55","first-page":"1518","article-title":"Analysis on post-marketing effectiveness and immunogenicity of enterovirus-A71 vaccine","volume":"41","author":"Hua","year":"2020","journal-title":"Chin. J. Epidemiol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1016\/j.vaccine.2019.12.025","article-title":"Effectiveness of enterovirus A71 vaccine in severe hand, foot, and mouth disease cases in Guangxi, China","volume":"38","author":"Jiang","year":"2020","journal-title":"Vaccine"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S2352-4642(19)30185-3","article-title":"Effectiveness of EV-A71 vaccination in prevention of paediatric hand, foot, and mouth disease associated with EV-A71 virus infection requiring hospitalisation in Henan, China, 2017\u20132018: A test-negative case-control study","volume":"3","author":"Li","year":"2019","journal-title":"Lancet Child Adolesc. Health"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2330163","DOI":"10.1080\/21645515.2024.2330163","article-title":"Effectiveness of Enterovirus 71 inactivated vaccines against hand, foot, and mouth disease: A test-negative case-control study","volume":"20","author":"Zhang","year":"2024","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_59","first-page":"252","article-title":"Post-marketing multi-center safety surveillance of inactivated enterovirus A71 vaccine (Vero cell)","volume":"53","author":"Zeng","year":"2019","journal-title":"Chin. J. Prev. Med."},{"key":"ref_60","first-page":"258","article-title":"Post-marketing observation on safety of inactivated enterovirus A71 vaccine (human diploid cell)","volume":"53","author":"Shen","year":"2019","journal-title":"Chin. J. Prev. Med."},{"key":"ref_61","first-page":"262","article-title":"Post-marketing safety analysis of inactivated enterovirus A71 vaccines","volume":"53","author":"Luo","year":"2019","journal-title":"Chin. J. Prev. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.vaccine.2021.01.048","article-title":"Post-marketing safety surveillance for inactivated Enterovirus 71 vaccines in Jiangsu, China from 2017 to 2019","volume":"39","author":"Gao","year":"2021","journal-title":"Vaccine"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Li, J., Xie, F., Lin, G., and Zhang, D. (2023). Immune Efficacy of the EV71 Vaccine in Fujian Province, China: A Real-World Analysis of HFMD. Vaccines, 11.","DOI":"10.3390\/vaccines11050944"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1080\/22221751.2022.2125346","article-title":"Molecular epidemiology and clinical features of hand, foot and mouth disease requiring hospitalization after the use of enterovirus A71 inactivated vaccine in chengdu, China, 2017-2022: A descriptive study","volume":"11","author":"Duan","year":"2022","journal-title":"Emerg. Microbes Infect."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"20909","DOI":"10.1038\/s41598-020-77768-7","article-title":"Epidemical and etiological study on hand, foot and mouth disease following EV-A71 vaccination in Xiangyang, China","volume":"10","author":"Meng","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"17028","DOI":"10.1038\/s41598-022-21312-2","article-title":"The spatial-temporal distribution and etiological characteristics of hand-foot-and-mouth disease before and after EV-A71 vaccination in Kunming, China, 2017\u20132020","volume":"12","author":"Wang","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Jiang, L., Jiang, H., Tian, X., Xia, X., and Huang, T. (2021). Epidemiological characteristics of hand, foot, and mouth disease in Yunnan Province, China, 2008\u20132019. BMC Infect. Dis., 21.","DOI":"10.1186\/s12879-021-06462-4"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Wang, W., Song, J., Wang, J., Li, Y., Deng, H., Li, M., Gao, N., Zhai, S., Dang, S., and Zhang, X. (2017). Cost-effectiveness of a national enterovirus 71 vaccination program in China. PLoS Negl. Trop. Dis., 11.","DOI":"10.1371\/journal.pntd.0005899"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Wu, J.T., Jit, M., Zheng, Y., Leung, K., Xing, W., Yang, J., Liao, Q., Cowling, B.J., Yang, B., and Lau, E.H. (2016). Routine Pediatric Enterovirus 71 Vaccination in China: A Cost-Effectiveness Analysis. PLoS Med., 13.","DOI":"10.1371\/journal.pmed.1002013"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Chen, Y., Xiao, Y., Ye, Y., Jiang, F., He, H., Luo, L., Chen, H., Shi, L., Mu, Q., and Chen, W. (2022). Immunogenicity and safety of an inactivated enterovirus 71 vaccine coadministered with trivalent split-virion inactivated influenza vaccine: A phase 4, multicenter, randomized, controlled trial in China. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1080408"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"5348","DOI":"10.1080\/21645515.2021.2010428","article-title":"Immunogenicity and safety of an inactivated enterovirus 71 vaccine co-administered with measles-mumps-rubella vaccine and live-attenuated Japanese encephalitis vaccine: A phase 4, single-center, randomized controlled trial","volume":"17","author":"Liu","year":"2021","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1093\/infdis\/jiz129","article-title":"Immunogenicity and Safety of an Inactivated Enterovirus 71 Vaccine Administered Simultaneously With Hepatitis B Vaccine and Group A Meningococcal Polysaccharide Vaccine: A Phase 4, Open-Label, Single-Center, Randomized, Noninferiority Trial","volume":"220","author":"Zhang","year":"2019","journal-title":"J. Infect. Dis."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Zhang, X., Zhang, Y., Li, H., and Liu, L. (2022). Hand-Foot-and-Mouth Disease-Associated Enterovirus and the Development of Multivalent HFMD Vaccines. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24010169"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness","year":"2021","journal-title":"Res. Synth. Methods"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/3\/235\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T13:39:03Z","timestamp":1772631543000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/3\/235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":74,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["vaccines14030235"],"URL":"https:\/\/doi.org\/10.3390\/vaccines14030235","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,4]]}}}